ID: ALA4098390

Max Phase: Preclinical

Molecular Formula: C96H157BrN34O20

Molecular Weight: 2187.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](Cc1ccc(Br)cc1)C(=O)O

Standard InChI:  InChI=1S/C96H157BrN34O20/c1-6-7-24-64(86(145)129-96(4,5)91(151)128-70(90(149)150)48-56-32-34-57(97)35-33-56)122-87(146)72-30-19-44-130(72)75(134)51-115-77(136)60(25-12-14-39-99)117-84(143)69(49-58-50-110-53-116-58)126-85(144)71(52-132)127-82(141)67(46-54(2)3)125-80(139)63(28-17-42-113-94(106)107)121-88(147)73-31-20-45-131(73)89(148)66(29-18-43-114-95(108)109)123-81(140)65(36-37-74(101)133)120-79(138)61(26-15-40-111-92(102)103)118-78(137)62(27-16-41-112-93(104)105)119-83(142)68(47-55-21-9-8-10-22-55)124-76(135)59(100)23-11-13-38-98/h8-10,21-22,32-35,50,53-54,59-73,132H,6-7,11-20,23-31,36-49,51-52,98-100H2,1-5H3,(H2,101,133)(H,110,116)(H,115,136)(H,117,143)(H,118,137)(H,119,142)(H,120,138)(H,121,147)(H,122,146)(H,123,140)(H,124,135)(H,125,139)(H,126,144)(H,127,141)(H,128,151)(H,129,145)(H,149,150)(H4,102,103,111)(H4,104,105,112)(H4,106,107,113)(H4,108,109,114)/t59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-/m0/s1

Standard InChI Key:  AJBLWPCBSXIKPI-RSUFIUMDSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 2187.43

Molecular Weight (Monoisotopic): 2185.1497

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. McKinnie SMK, Wang W, Fischer C, McDonald T, Kalin KR, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC..  (2017)  Synthetic Modification within the "RPRL" Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation.,  60  (14): [PMID:28685579] [10.1021/acs.jmedchem.7b00723]

2. Fischer C, Lamer T, Wang W, McKinnie SMK, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC..  (2019)  Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents.,  166  [PMID:30690406] [10.1016/j.ejmech.2019.01.040]

3. Fernandez KX, Fischer C, Vu J, Gheblawi M, Wang W, Gottschalk S, Iturrioz X, Llorens-Cortés C, Oudit GY, Vederas JC..  (2021)  Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators.,  12  (8.0): [PMID:34458742] [10.1039/D1MD00120E]

Source

Source(1):

• Scientific Literature